HK1114851A1 - Polycyclic indazole derivatives that are erk inhibitors - Google Patents
Polycyclic indazole derivatives that are erk inhibitorsInfo
- Publication number
- HK1114851A1 HK1114851A1 HK08110160.5A HK08110160A HK1114851A1 HK 1114851 A1 HK1114851 A1 HK 1114851A1 HK 08110160 A HK08110160 A HK 08110160A HK 1114851 A1 HK1114851 A1 HK 1114851A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- indazole derivatives
- erk inhibitors
- polycyclic
- polycyclic indazole
- erk
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74985605P | 2005-12-13 | 2005-12-13 | |
PCT/US2006/046959 WO2007070398A1 (en) | 2005-12-13 | 2006-12-11 | Polycyclic indazole derivatives that are erk inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1114851A1 true HK1114851A1 (en) | 2008-11-14 |
Family
ID=37969564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK08110160.5A HK1114851A1 (en) | 2005-12-13 | 2008-09-12 | Polycyclic indazole derivatives that are erk inhibitors |
Country Status (29)
Country | Link |
---|---|
US (1) | US20070191604A1 (ko) |
EP (1) | EP1966151B1 (ko) |
JP (1) | JP4881957B2 (ko) |
KR (1) | KR101417136B1 (ko) |
CN (1) | CN101370784B (ko) |
AR (1) | AR056891A1 (ko) |
AT (1) | ATE527240T1 (ko) |
AU (1) | AU2006326616B2 (ko) |
BR (1) | BRPI0619823B8 (ko) |
CA (1) | CA2633023C (ko) |
CY (1) | CY1112760T1 (ko) |
DK (1) | DK1966151T3 (ko) |
EC (1) | ECSP088550A (ko) |
ES (1) | ES2372976T3 (ko) |
HK (1) | HK1114851A1 (ko) |
HR (1) | HRP20110892T1 (ko) |
IL (1) | IL192034A (ko) |
MY (1) | MY149430A (ko) |
NO (1) | NO341831B1 (ko) |
NZ (1) | NZ569087A (ko) |
PE (2) | PE20071095A1 (ko) |
PL (1) | PL1966151T3 (ko) |
PT (1) | PT1966151E (ko) |
RS (1) | RS51981B (ko) |
RU (1) | RU2442778C9 (ko) |
SI (1) | SI1966151T1 (ko) |
TW (1) | TWI344466B (ko) |
WO (1) | WO2007070398A1 (ko) |
ZA (1) | ZA200805525B (ko) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8546404B2 (en) * | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
CA2642762A1 (en) * | 2006-02-16 | 2007-08-30 | Schering Corporation | Pyrrolidine derivatives as erk inhibitors |
KR20090042779A (ko) | 2006-06-30 | 2009-04-30 | 쉐링 코포레이션 | P53 활성을 증가시키는 치환된 피페리딘 및 이의 사용 |
EP2155722B1 (en) * | 2007-06-05 | 2013-08-14 | Merck Sharp & Dohme Corp. | Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer |
TWI444379B (zh) | 2007-06-29 | 2014-07-11 | Sunesis Pharmaceuticals Inc | 有用於作為Raf激酶抑制劑之化合物 |
EP2220503A1 (en) * | 2007-11-30 | 2010-08-25 | Schering Corporation | Braf biomarkers |
JP5276676B2 (ja) * | 2008-02-21 | 2013-08-28 | メルク・シャープ・アンド・ドーム・コーポレーション | Erk阻害剤である化合物 |
AU2009222144A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Pyrazole [3, 4-b] pyridine Raf inhibitors |
US20110278332A1 (en) * | 2009-03-26 | 2011-11-17 | Protexer, Inc. | Shoe cover removal apparatus |
US8637554B2 (en) * | 2008-05-07 | 2014-01-28 | The Trustees Of The University Of Pennsylvania | Methods for treating thyroid cancer |
EP2316031B1 (en) * | 2008-08-19 | 2016-09-14 | Merck Sharp & Dohme Corp. | IL-8 biomarker for monitoring cancer treatment |
US9229008B2 (en) | 2008-08-19 | 2016-01-05 | Merck Sharp & Dohme Corp. | IL-8 level as a determinant of responsivity of a cancer to treatment |
EP2448942B1 (en) | 2009-07-02 | 2014-09-24 | Merck Sharp & Dohme Corp. | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS |
EP2483263B1 (en) * | 2009-09-30 | 2018-07-18 | Merck Sharp & Dohme Corp. | Heterocyclic compounds that are erk inhibitors |
EA023838B1 (ru) | 2009-10-14 | 2016-07-29 | Мерк Шарп Энд Домэ Корп. | ЗАМЕЩЕННЫЕ ПИПЕРИДИНЫ, КОТОРЫЕ ПОВЫШАЮТ АКТИВНОСТЬ p53, И ИХ ПРИМЕНЕНИЕ |
WO2011123937A1 (en) * | 2010-04-06 | 2011-10-13 | University Health Network | Kinase inhibitors and method of treating cancer with same |
EP2584903B1 (en) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
CA2819373A1 (en) * | 2010-12-09 | 2012-06-14 | Amgen Inc. | Bicyclic compounds as pim inhibitors |
EP2654748B1 (en) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
JP2014510105A (ja) | 2011-03-22 | 2014-04-24 | アムジエン・インコーポレーテツド | Pim阻害剤としてのアゾール化合物 |
AU2012245971A1 (en) | 2011-04-21 | 2013-10-17 | Piramal Enterprises Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
WO2013016164A1 (en) | 2011-07-26 | 2013-01-31 | Merck Sharp & Dohme Corp. | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS |
WO2013062923A1 (en) | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp. | MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
US9062071B2 (en) | 2011-12-21 | 2015-06-23 | Merck Sharp & Dohme Corp. | Substituted piperidines as HDM2 inhibitors |
WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
ITMI20120135A1 (it) * | 2012-02-02 | 2013-08-03 | Diab Int Ab | Procedimento per la produzione di schiume di pet e schiume di pet ottenute con questo procedimento |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
CN103450163B (zh) * | 2012-05-29 | 2017-06-23 | 中国医学科学院药物研究所 | 吲唑类化合物、其制备方法及其药物用途 |
IN2015DN01328A (ko) | 2012-09-19 | 2015-07-03 | Novartis Ag | |
JP6280554B2 (ja) * | 2012-09-28 | 2018-02-14 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Erk阻害剤である新規化合物 |
TW201429969A (zh) | 2012-12-20 | 2014-08-01 | Merck Sharp & Dohme | 作爲hdm2抑制劑之經取代咪唑吡啶 |
WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
EP3046557A1 (en) | 2013-09-20 | 2016-07-27 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
DK3063143T3 (en) | 2013-11-01 | 2018-08-20 | Novartis Ag | Amino heteroaryl benzamides as kinase inhibitors |
WO2015156674A2 (en) | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
WO2016095088A1 (en) * | 2014-12-15 | 2016-06-23 | Merck Sharp & Dohme Corp. | Erk inhibitors |
WO2016095089A1 (en) | 2014-12-15 | 2016-06-23 | Merck Sharp & Dohme Corp. | Erk inhibitors |
EP3355923B1 (en) | 2015-10-01 | 2022-02-23 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Histone deacetylase inhibitors for use in the treatment of drug resistant melanoma |
MX2018004643A (es) | 2015-10-21 | 2018-08-01 | Otsuka Pharma Co Ltd | Compuestos de benzolactama como inhibidores de la proteina cinasa. |
WO2017099591A1 (en) | 2015-12-07 | 2017-06-15 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Treatment of inhibitor resistant braf-mutant cancers |
WO2017156495A1 (en) * | 2016-03-11 | 2017-09-14 | Corvus Pharmaceuticals, Inc. | Compounds and methods for modulating bruton's tyrosine kinase |
WO2017204626A1 (en) | 2016-05-24 | 2017-11-30 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Combination therapy - combined map2k4/map3k1 and mek/erk inhibition |
WO2018067512A1 (en) | 2016-10-05 | 2018-04-12 | Kalyra Pharmaceuticals, Inc. | Spirocyclic compounds |
GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
JP6557436B1 (ja) | 2018-03-12 | 2019-08-07 | アッヴィ・インコーポレイテッド | チロシンキナーゼ2媒介性シグナル伝達の阻害剤 |
CN114605329B (zh) * | 2022-03-28 | 2024-01-26 | 河南中医药大学 | 取代的吲唑甲酰胺或取代的氮杂吲唑甲酰胺类flt3抑制剂及其用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9213077D0 (en) | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
BR0104424A (pt) * | 2000-02-05 | 2002-01-08 | Vertex Pharma | Composições de pirazol úteis como inibidores de erk |
US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
JP4648703B2 (ja) * | 2002-09-05 | 2011-03-09 | アベンティス・ファーマ・ソシエテ・アノニム | 医薬としての新規なアミノインダゾール誘導体及びこれらを含む医薬組成物 |
-
2006
- 2006-12-11 RU RU2008128119/04A patent/RU2442778C9/ru active
- 2006-12-11 WO PCT/US2006/046959 patent/WO2007070398A1/en active Application Filing
- 2006-12-11 NZ NZ569087A patent/NZ569087A/en not_active IP Right Cessation
- 2006-12-11 RS RS20110516A patent/RS51981B/en unknown
- 2006-12-11 PT PT06845064T patent/PT1966151E/pt unknown
- 2006-12-11 PL PL06845064T patent/PL1966151T3/pl unknown
- 2006-12-11 US US11/636,954 patent/US20070191604A1/en not_active Abandoned
- 2006-12-11 KR KR1020087016729A patent/KR101417136B1/ko active IP Right Grant
- 2006-12-11 MY MYPI20082076A patent/MY149430A/en unknown
- 2006-12-11 JP JP2008545685A patent/JP4881957B2/ja active Active
- 2006-12-11 DK DK06845064.2T patent/DK1966151T3/da active
- 2006-12-11 CA CA2633023A patent/CA2633023C/en active Active
- 2006-12-11 AT AT06845064T patent/ATE527240T1/de active
- 2006-12-11 SI SI200631221T patent/SI1966151T1/sl unknown
- 2006-12-11 EP EP06845064A patent/EP1966151B1/en active Active
- 2006-12-11 AU AU2006326616A patent/AU2006326616B2/en not_active Ceased
- 2006-12-11 ES ES06845064T patent/ES2372976T3/es active Active
- 2006-12-11 BR BRPI0619823A patent/BRPI0619823B8/pt active IP Right Grant
- 2006-12-11 CN CN2006800527776A patent/CN101370784B/zh active Active
- 2006-12-12 AR ARP060105474A patent/AR056891A1/es active IP Right Grant
- 2006-12-12 TW TW095146375A patent/TWI344466B/zh not_active IP Right Cessation
- 2006-12-12 PE PE2006001592A patent/PE20071095A1/es active IP Right Grant
- 2006-12-12 PE PE2010000279A patent/PE20100562A1/es not_active Application Discontinuation
-
2008
- 2008-06-10 IL IL192034A patent/IL192034A/en active IP Right Grant
- 2008-06-13 EC EC2008008550A patent/ECSP088550A/es unknown
- 2008-06-24 ZA ZA200805525A patent/ZA200805525B/xx unknown
- 2008-07-11 NO NO20083114A patent/NO341831B1/no not_active IP Right Cessation
- 2008-09-12 HK HK08110160.5A patent/HK1114851A1/xx not_active IP Right Cessation
-
2011
- 2011-11-30 HR HR20110892T patent/HRP20110892T1/hr unknown
-
2012
- 2012-01-04 CY CY20121100006T patent/CY1112760T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1114851A1 (en) | Polycyclic indazole derivatives that are erk inhibitors | |
IL198247A0 (en) | Indazole derivatives useful as l-cpt1 inhibitors | |
TWI370127B (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
ZA200710951B (en) | Piperidinyl-substituted isoquinolone derivatives as Rhokinase inhibitors | |
HUE038246T2 (hu) | Heterobifunkcionális pan-szelektin inhibitorok | |
IL185185A0 (en) | Azolylacylguanidines as ??-secretase inhibitors | |
IL221573A0 (en) | Imidazoquinolines as lipid kinase inhibitors | |
IL193413A0 (en) | Pyrrolidine derivatives as erk inhibitors | |
HK1114380A1 (en) | Pyrrolopyrazoles as kinase inhibitors | |
IL190078A0 (en) | Kinase inhibitors | |
HK1105592A1 (en) | Aryl-pyridine derivatives as 1-beta-hsd1 inhibitors | |
HK1107348A1 (en) | Indozolone derivatives as 11b-hsd1 inhibitors | |
PL1943243T3 (pl) | Inhibitory kinazy | |
EP1968581A4 (en) | TETRACYCLIC KINASE INHIBITORS | |
IL189112A0 (en) | NOVEL HETEROCYCLIC NF-kB INHIBITORS | |
GB0516967D0 (en) | Inhibitors | |
IL189985A0 (en) | Kinase inhibitors | |
ZA200803287B (en) | Kinase inhibitors | |
ZA200706212B (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20221209 |